Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors from the central nervous program, conolidine modulates alternate molecular targets. A Science Improvements review discovered that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://donaldh874oqs6.gynoblog.com/profile